Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Keyphrases

• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Tolerability 100%
• HLA-A*02 100%
• Single-arm Study 80%
• Pembrolizumab 60%
• Antitumor Activity 40%
• Antigen Expression 40%
• HLA-A 40%
• New York Esophageal Squamous Cell carcinoma-1 40%
• Number of Patients 20%
• Genetic Modification 20%
• Targeted Expression 20%
• Safety Profile 20%
• T Cell Receptor 20%
• Non-small Cell Lung Cancer (NSCLC) 20%
• Anti-tumor Response 20%
• Serious Adverse Events 20%
• Durable Response 20%
• T Cell Expansion 20%
• Treatment Emergent 20%
• Method Study 20%
• Cytopenia 20%
• Leukapheresis 20%
• Patient Study 20%
• Safety Response 20%
• Treatment-related 20%
• Cytokine Release Syndrome 20%
• Recurrent Non-small Cell Lung Cancer 20%
• Pharmacokinetic Data 20%
• Autologous T Cell 20%
• Shared Epitope 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Tolerability 100%
• Pembrolizumab 100%
• Gsk 3377794 100%
• Antitumor Activity 66%
• Esophageal Squamous Cell Carcinoma 66%
• Promazine 66%
• Adverse Event 33%
• T Lymphocyte Receptor 33%
• Cytopenia 33%
• Epitope 33%
• Cytokine Release Syndrome 33%
• Pharmacokinetics 33%